No Data
No Data
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Traditional Chinese medicine stocks strengthened independently. At one point, Hanson Pharmaceuticals hit the market. Ma Yinglong rose by more than 6%, and China Resources rose by more than 5%, followed by Daren Tang and Fangsheng Pharmaceuticals.
Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significa
Tianfeng Securities released a research report on April 19 stating that Daren Tang (600329.SH) was rated to increase its holdings. The main reasons for the rating include: 1) the “three core and nine wings” strategy is progressing steadily, with significant growth in core products; 2) steady improvement in profitability; and 3) impressive growth in overseas markets. (Mainichi Keizai Shimbun)
A-share changes | Daren Tang rose 8% in the afternoon, and industrial revenue reached a new high last year
Glonghui, April 1 | Daren Tang (600329.SH) increased its increase to 8% in the afternoon, and the stock price returned to the 30 yuan mark, with a total market value of 23.08 billion yuan. The company announced after the market on Friday that net profit for 2023 was 987 million yuan, an increase of 14.49% over the previous year, and plans to distribute 10 12.8 yuan. Among them, the company's industrial revenue was 4.930 billion yuan, maintaining double-digit year-on-year growth and reaching a new high. According to Fangzheng Securities reviews, the company has achieved remarkable results in deepening its core products, and its performance has exceeded expectations. Maintain a “Recommended” rating.
Daren Tang (600329.SH) announced its 2023 annual results, with net profit of 987 million yuan, an increase of 14.49% over the previous year. It plans to distribute 10 to 12.8 yuan
According to the Zhitong Finance App, Daren Tang (600329.SH) disclosed the 2023 annual report. The company achieved revenue of 8.222 billion yuan in 2023, a year-on-year decrease of 0.33%; net profit to mother of 987 million yuan, an increase of 14.49%; deducted non-net profit of 952 million yuan, an increase of 23.8%; and basic earnings per share of 1.28 yuan. The company plans to distribute a cash dividend of 12.8 yuan (tax included) for every 10 shares to all shareholders. In 2023, the company will firmly implement “focus on the market, effective innovation, organizational governance, co-creation and sharing, drive both industry and finance, control capital and loss, digital empowerment, and cultural goods
Singapore Index Slips Into Red on Weak US Data; OCBC Shares Close Flat Following Pricing of Perpetual Capital Securities
Singapore's Straits Times Index erased yesterday's gains to close in the negative territory on Wednesday, tracking overnight losses on Wall Street after newly released US trade data showed a weakening
Daren Tang fell to a standstill. Industry insiders revealed that it may be related to the mixed reform of the majority shareholders
Gelonghui, January 10 | According to brokerage China, Daren Tang suddenly fell to a standstill today. According to Daren Tang's announcement, the incident may be due to the fact that 70 million shares of the company's shares held by Tianjin Pharmaceutical Group Co., Ltd., the controlling shareholder of the company were frozen, and the applicant for the freeze was the Shanghai Supervisory Commission. The reason for the application was to handle the case. “A situation where the supervisory authority of one place freezes state-owned assets in another place.” Very rare. So what exactly is the reason? Industry insiders revealed that this may be related to the mixed reform of Tianjin Pharmaceutical Group, the majority shareholder of Daren Tang. At the end of 2020, Tianjin Jinlian Investment Holdings Co., Ltd. and Shanghai Industrial Group Co., Ltd. held a mixed reform agreement with Tianjin Pharmaceutical Group
No Data